KineMed Wins $225K SBIR Contract to Develop Myocardial Fibrosis Biomarkers | GenomeWeb

NEW YORK (GenomeWeb News) – KineMed said today that it has received a $225,000 Phase I Small Business Innovation Research contract from the National Heart, Lung, and Blood Institute for research into biomarkers for the early detection of myocardial fibrosis.

The contract is focused specifically on developing non-invasive methods to detect and monitor myocardial fibrosis in vivo. In previous work, KineMed has identified via its Dynamic Proteomics technology blood proteins that may potentially serve as markers of the fibrotic process in remodeling heart tissue.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.

A man is using DNA evidence to argue that he is the rightful heir to the baronetcy of Stichill, the Guardian reports.

As part of an effort to get a diverse group of people to donate their DNA for research, some blood donors in the San Diego area will get their genomes sequenced, according to KPBS.

The comment period on the Department of Health and Human Services' proposal to alter the Common Rule has been extended.